Entecavir

Authors:

Abstract
Entecavir (Baraclude™) is a novel nucleoside analogue of 2′-deoxyguanosine whose intracellular triphosphate form inhibits replication of the hepatitis B virus (HBV). In large, randomised, double-blind, phase III clinical trials in patients with chronic HBV infection, oral entecavir 0.5 or 1.0mg once daily for up to 96 weeks was superior to lamivudine 100 mg/day in improving hepatic histology, normalising aminotransferase levels and suppressing viraemia to levels undetectable by polymerase chain reaction (PCR) assay in nucleoside-naive hepatitis Be antigen (HBeAg)-negative (precore or core promoter mutants) and/or HBeAg-positive patients, and in lamivudine-refractory (persistent viraemia during lamivudine therapy) HBeAg-positive patients. In addition, the tolerability profile of entecavir was generally similar to that of lamivudine. Thus, entecavir is a primary option in the treatment of chronic HBV infection in both nucleoside-naive and lamivudine-refractory patients. Entecavir undergoes rapid intracellular conversion into an active 5′-triphosphate form that inhibits HBV replication in a dose-dependent manner. Entecavir was up to 2200-fold more potent than lamivudine in reducing the secretion of viral DNA from infected cells in culture, retained activity against HBV variants resistant to lamivudine, carbovir, emtricitabine or clevudine in vitro, and suppressed viraemia in animal models of chronic HBV infection. The development of phenotypic resistance to entecavir has occurred infrequently in clinical trials and requires the presence of pre-existing mutations associated with lamivudine resistance and at least three mutations in the HBV viral polymerase. In humans, orally administered entecavir was rapidly absorbed in a dose-dependent manner, with a mean maximum steady-state plasma concentration (Cmax) of 4–7 ng/mL after a 0.5mg dose and 8–12 ng/mL after a 1.0mg dose, achieved in a median time of 0.6–1.0 hour. Steady-state concentrations were achieved after 6–10 days with ≈2-fold accumulation, with a mean area under the plasma concentration-time curve (AUC) during a dosage interval at steady state that was also dose dependent (15–36 ng · h/mL). Concomitant administration of entecavir with food results in a ≈40% decrease in Cmax and a ≈20% decrease in AUC. Entecavir is extensively distributed into tissues, and plasma protein binding in vitro was ≈13%. Elimination occurred primarily via a renal route (62–80% of the drug eliminated), with a terminal half-life estimated at ≈128–149 hours and a renal clearance of 22–28 L/h following multiple-dose administration. Renal impairment causes accumulation of entecavir, but pharmacokinetic parameters were not altered significantly by moderate to severe hepatic impairment. Entecavir 0.5 mg/day was more effective than lamivudine 100 mg/day after 48 weeks' treatment in three randomised, double-blind trials in HBeAg-positive or -negative nucleoside-naive patients. A significantly greater proportion of entecavir than lamivudine recipients had a histological improvement in their liver biopsy (primary endpoint), irrespective of whether they were HBeAg-positive (72% vs 62%) or HBeAg-negative (70% vs 61%). In addition, in a mixed population of HBeAg-positive and -negative Chinese patients, the proportion of patients with undetectable levels of HBV DNA (measured by branched chain assay [HBV bDNA]) and normalised serum ALT levels was greater in entecavir than in lamivudine recipients (primary composite endpoint; 90% vs 67%). In lamivudine-refractory, HBeAg-positive patients, significantly more entecavir 1 mg/day than lamivudine 100 mg/day recipients achieved the co-primary endpoints, a histological improvement in their liver biopsy (55% vs 28%), or an undetectable serum HBV bDNA level and normalisation of serum ALT level (composite endpoint; 55% vs 4%) after 48 weeks of treatment. After 2 years of treatment, 80% of HBeAg-positive and 94% of HBeAgnegative nucleoside-naive entecavir recipients had undetectable levels of HBV DNA by PCR (<300 copies/mL), compared with 39% and 77% of lamivudine recipients, while in lamivudine-refractory HBeAg-positive patients viral suppression was achieved in 30% of entecavir versus <1% of lamivudine recipients. Overall, entecavir 0.5 or 1 mg/day had an adverse-event profile similar to that of lamivudine. Adverse events were mostly mild to moderate in severity and the most frequent (≥10%) adverse events reported in entecavir recipients in phase III trials were headache, upper respiratory tract infection, cough, nasopharyngitis, upper abdominal pain, fatigue and fever. In phase III trials, the incidence of on-treatment serum ALT flares among lamivudine-naive patients did not differ significantly between entecavir (<1–4%) and lamivudine (3–6%) recipients. In lamivudine-refractory patients, <1% of entecavir and 11% of lamivudine recipients experienced ALT flares. Serious adverse events were experienced by 3–10% of entecavir and 5–8% of lamivudine recipients whether they were nucleoside naive or lamivudine refractory.

This publication has 38 references indexed in Scilit: